In summary, the present study, together with our previous study, reveals that mGluR1 inhibition is a useful strategy to recover D1 receptor signaling in the Fmr1KO mice, and that combination of Grp1 mGluR antagonist and D1 agonist is a potential drug therapy for the FXS. This evidence concerns the gene GRM1 and fragile X syndrome.